Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P

PURPOSE: A phase II study was conducted to determine the response rate of ixabepilone (BMS-247550, National Cancer Institute (NCI)–supplied agent investigational new drug No. 59,699) in patients with persistent or recurrent endometrial cancer who have progressed despite standard therapy. PATIENTS AN...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Dizon, Don S., Blessing, John A., McMeekin, D. Scott, Sharma, Sudarshan K., DiSilvestro, Paul, Alvarez, Ronald D.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2009
Предметы:
Original Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2716935/
https://ncbi.nlm.nih.gov/pubmed/19451430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.6995
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы